Reimagine Care is using its own nurses and technology to help community oncology practices build programs for complex cancer therapies such as CAR-T and grow them without hiring n ...
Biosimilars can cost $600 a month versus $6,000 for branded rivals, but PBM rebate incentives push formularies toward pricier ...
The newest wave of cancer therapies, including CAR-T cell therapy, bispecific antibodies and antibody-drug conjugates, is ...
Lean MASLD/MASH comprises a meaningful subset of patients, with lean MASH linked to higher all-cause mortality and liver events despite lower cardiometabolic comorbidity than obese disease. Adding ...
A post-2018 16.8% rise in Hispanic HIV incidence in anti-sanctuary counties temporally aligned with public charge expansion to Medicaid, consistent with deterrence from prevention, testing, and ...
In this discussion, Ohio State economist Eric Seiber, Ph.D., explains how inconsistent claims-data definitions can skew ...
CMS’ mandatory GLOBE drug model ties some Medicare Part B rebates to global prices, but cuts projected savings sharply amid ...
Some predicted that drugmakers might boost launch prices to make up for Medicare drug negotiations shrinking profits. Harvard ...
State PBM reform accelerates through 2026, with Theresa Carnegie of Mintz unpacking new laws, rebate pass-through, spread ...
CPT under-specification for molecular diagnostics promotes widespread use of unclassified codes, undermining payer coverage ...
Fewer than one in five young people with first episode psychosis filled enough antipsychotic prescriptions to be considered ...
Dunn of NeosRx says a 340B shift from discounts to rebates likely won't affect rebate erosion affecting plan sponsors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results